Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -6.16% is 73% above its 5-year average of -23.06%, near the high end of its 5-year range (-43.08%–-5.40%).
68.83% above its 12-month average of -19.77%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.85%.
RETURN ON ASSETS (ROA)
-6.16%
RETURN ON ASSETS (ROA) AVG TTM
-19.77%
RETURN ON ASSETS (ROA) AVG 3Y
-17.54%
RETURN ON ASSETS (ROA) AVG 5Y
-23.06%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.83%
CURRENT VS 3Y AVG
+64.88%
CURRENT VS 5Y AVG
+73.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.94%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-224.70%
vs the sector median at left
Beam Therapeutics Inc.
Market Cap
$2.51B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.74B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.14B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$1.73B
Return on Assets (ROA)
-10.49%
TTM Avg
-13.41%
3Y Avg
-10.26%
5Y Avg
-6.23%
Market Cap
$1.72B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.00B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$472.39M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$459.30M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
Market Cap
$397.55M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | -6.16% | -19.77% | -17.54% | -23.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 10.36% | 11.11% | 1.40% | -7.68% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -42.79% | -37.88% | -40.02% | -36.63% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | -10.49% | -13.41% | -10.26% | -6.23% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | -46.66% | -46.30% | -40.19% | -33.55% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -6.43% | -17.46% | -82.63% | -55.94% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | -3.84% | -6.38% | -6.57% | -4.38% |
| NRC Health (NRC)vs › | $459.30M | 4.30% | 13.65% | 19.24% | 21.45% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | -23.05% | -30.00% | -27.77% | -27.77% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | -382.32% | -98.02% | -80.35% | -65.77% |
ROA
-6.2%
ROE
-8.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -5.40% |
| 2024-12-31 | -34.13% |
| 2023-12-31 | -9.08% |
| 2022-12-31 | -21.55% |
| 2021-12-31 | -25.14% |
| 2020-12-31 | -43.08% |
| 2019-12-31 | -50.18% |
| 2018-12-31 | -69.01% |
| 2017-12-31 | -363.42% |
